Related Experiment Video
Updated: Jun 13, 2026
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
Published on: November 9, 2018
Minocycline recovers MTT-formazan exocytosis impaired by amyloid beta peptide
Peter Kreutzmann1, Gerald Wolf, Kathleen Kupsch
1Institute of Medical Neurobiology, Otto-von-Guericke University Magdeburg, Leipziger Str. 44, Magdeburg, Germany. peter.kreutzmann@med.ovgu.de
Abstract:
Minocycline, a tetracycline antibiotic, has been reported to exert beneficial effects in models of Alzheimer's disease (AD). To characterize the mechanisms underlying the putative minocycline-related neuroprotection, we studied its effect in an in vitro model of AD. Primary hippocampal cultures were treated with β-amyloid peptide (Aβ) and cell viability was assessed by standard MTT-assay. Incubation with 10 μM Aβ for 24 h significantly inhibits cellular MTT-reduction without inducing morphological signs of enhanced cell death or increase in release of lactate dehydrogenase. This indicates that cell viability was not affected. The inhibition of MTT-reduction by Aβ was due to an acceleration of MTT-formazan exocytosis. Intriguingly, the Aβ-triggered increase in MTT-formazan exocytosis was abolished by co-treatment with minocycline. In vehicle-treated cells minocycline had no effect on formazan exocytosis. This hitherto unrecognized property of minocycline has to be noticed in the elucidation of the underlying mechanism of this promising neuroprotectant.
Insights
Minocycline, an antibiotic, prevents beta-amyloid from affecting cell viability assays in Alzheimer's disease models. This study uncovers a novel mechanism for minocycline's neuroprotective potential.
Area of Science:
- Neuroscience
- Pharmacology
- Cell Biology
Background:
- Alzheimer's disease (AD) is a neurodegenerative disorder.
- Minocycline, a tetracycline antibiotic, shows potential neuroprotective effects in AD models.
- The precise mechanisms of minocycline's neuroprotection require further elucidation.
Purpose of the Study:
- To investigate the effects of minocycline on beta-amyloid peptide (Aβ)-induced changes in an in vitro model of Alzheimer's disease.
- To characterize the cellular mechanisms underlying minocycline's potential neuroprotective actions.
Main Methods:
- Primary hippocampal cultures were utilized as an in vitro model of AD.
- Cells were treated with beta-amyloid peptide (Aβ).
- Cell viability was assessed using the MTT assay, and lactate dehydrogenase release was measured.
Main Results:
- Aβ treatment inhibited MTT reduction, but did not increase cell death or lactate dehydrogenase release, indicating preserved cell viability.
- Aβ-induced inhibition of MTT reduction was attributed to accelerated MTT-formazan exocytosis.
- Minocycline co-treatment abolished the Aβ-triggered increase in MTT-formazan exocytosis.
- Minocycline alone did not affect formazan exocytosis in vehicle-treated cells.
Conclusions:
- Minocycline exhibits a previously unrecognized effect on MTT-formazan exocytosis in the context of Aβ exposure.
- This finding provides a novel insight into the mechanism of minocycline's neuroprotection in Alzheimer's disease models.
- Further research into this property of minocycline is warranted to fully understand its therapeutic potential.
